CORDIS
EU research results

CORDIS

English EN
Boost Brittle Bones Before Birth

Boost Brittle Bones Before Birth

Objective

Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal mesenchymal stem cells (MSC) is a promising approach for treatment of OI. We receive regular requests for MSC transplantation from patients and their physicians; patient organisations support our approach.
The principal objective of the BOOSTB4 project is to conduct a Phase I/II clinical trial of the safety and efficacy of pre- and/or postnatal MSC transplantation in the severest forms of OI (type III, severe type IV). Transplantation before birth at the onset of disease should lead to greater efficacy and engraftment with less rejection than transplantation after birth. Postnatal transplantation will be evaluated in cases where prenatal diagnosis was not made. The trial’s primary outcome is safety; secondary outcomes relate to efficacy (fracture frequency, growth, bone mineral density and quality of life). All patients will undergo molecular diagnosis to confirm OI before inclusion in the trial. Non-invasive prenatal diagnosis will be developed and validated.
The BOOSTB4 consortium is led by experts in MSC, prenatal therapy and OI at the Karolinska Institutet (KI), which will also lead the international multicentre trial; five additional EU centres of excellence are included. Ethical and regulatory applications are underway to conduct this clinical trial. These are facilitated by the ethical and regulatory approvals for prenatal MSC transplantation in 10 cases of OI that have already been granted at KI.
Successful prenatal transplantation represents a major step forward in the management of patients with severe OI, and beyond, to a range of other inherited birth defects.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 827 061,50

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 648 543,75

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 408 395

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 703 132,50

GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 1 410 493,25

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 241 156

CELLPROTECT NORDIC PHARMACEUTICALS AB

Sweden

EU Contribution

€ 549 781,25

NORDIC HEALTH ECONOMICS AB

Sweden

EU Contribution

€ 106 000

MEDSCINET AB

Sweden

EU Contribution

€ 121 093,75

EURAM LIMITED

United Kingdom

EU Contribution

€ 77 275

UNIVERSITY OF LEICESTER

United Kingdom

EU Contribution

€ 50 000

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 262 097,50

A2F ASSOCIATES LIMITED

United Kingdom

EU Contribution

€ 203 725

Project information

Grant agreement ID: 681045

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 8 378 755,75

  • EU contribution

    € 6 608 754,50

Coordinated by:

KAROLINSKA INSTITUTET

Sweden